Deucravacitinib Shows Promise in Treating Psoriasis with Eczematous Features
A study is evaluating the efficacy and safety of deucravacitinib in patients with Psoriasis Eczema (PsEma) over 16 weeks.
Therapeutic Area
Therapeutic area intelligence for Psoriasis and Eczema with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.